169 related articles for article (PubMed ID: 37075146)
1. Immune Checkpoint Inhibitors - The Need for Innovation.
Johnson PC; Gainor JF; Sullivan RJ; Longo DL; Chabner B
N Engl J Med; 2023 Apr; 388(16):1529-1532. PubMed ID: 37075146
[No Abstract] [Full Text] [Related]
2. How to select cancer patients for immunotherapy.
Pfeiffer P; Qvortrup C; Hansen KH
EBioMedicine; 2021 Jan; 63():103184. PubMed ID: 33418504
[No Abstract] [Full Text] [Related]
3. Immune checkpoint inhibitor associated neurotoxicity: Much more than meets the eye.
Raibagkar P
Immunol Lett; 2020 May; 221():72-74. PubMed ID: 32092358
[No Abstract] [Full Text] [Related]
4. A Novel Etiology of Hypophysitis: Immune Checkpoint Inhibitors.
Fernandes S; Varlamov EV; McCartney S; Fleseriu M
Endocrinol Metab Clin North Am; 2020 Sep; 49(3):387-399. PubMed ID: 32741478
[TBL] [Abstract][Full Text] [Related]
5. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors.
Galluzzi L; Humeau J; Buqué A; Zitvogel L; Kroemer G
Nat Rev Clin Oncol; 2020 Dec; 17(12):725-741. PubMed ID: 32760014
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint blockade for patients with lung cancer and idiopathic pulmonary fibrosis.
Duchemann B; Pluvy J; Crestani B; Zalcman G; Nunes H
Eur J Cancer; 2021 Mar; 145():179-182. PubMed ID: 33486441
[No Abstract] [Full Text] [Related]
7. A case of Schönlein-Henoch purpura induced by immune checkpoint inhibitor in a patient with metastatic melanoma.
Belkaid S; Berger M; Nouvier M; Picard C; Dalle S
Eur J Cancer; 2020 Nov; 139():169-172. PubMed ID: 32992155
[No Abstract] [Full Text] [Related]
8. [Immune Checkpoint Inhibitors-induced Myasthenia Gravis: From Diagnosis to Treatment].
Yao S; Li X; Nong J; Zhang Y
Zhongguo Fei Ai Za Zhi; 2020 Aug; 23(8):685-688. PubMed ID: 32752585
[TBL] [Abstract][Full Text] [Related]
9. Onset of subacute cutaneous lupus erythematosus after the initiation of immune checkpoint inhibitor therapy of cancer.
Gambichler T; Doerler M; Scheel CH
Lupus; 2021 Mar; 30(3):531-533. PubMed ID: 33407044
[No Abstract] [Full Text] [Related]
10. Pembrolizumab in the Treatment of Breast Cancer.
Pivot X
N Engl J Med; 2022 Jul; 387(3):273-274. PubMed ID: 35857664
[No Abstract] [Full Text] [Related]
11. [New AMM: Nivolumab for advanced oesophageal squamous cell carcinomia after first line of chemotherapy].
Reich M; Coutzac C
Bull Cancer; 2021 Mar; 108(3):228-229. PubMed ID: 33531154
[No Abstract] [Full Text] [Related]
12. Ophthalmic adverse effects of immune checkpoint inhibitors: the Mayo Clinic experience.
Fortes BH; Liou H; Dalvin LA
Br J Ophthalmol; 2021 Sep; 105(9):1263-1271. PubMed ID: 32830124
[TBL] [Abstract][Full Text] [Related]
13. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM
Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
[TBL] [Abstract][Full Text] [Related]
14. Gastrointestinal: Severe gastritis with complete gastric mucosal sloughing.
Nasser R; Fisher Y; Klein A
J Gastroenterol Hepatol; 2021 Oct; 36(10):2639. PubMed ID: 33624341
[No Abstract] [Full Text] [Related]
15. CTLA-4 Blockade Resistance after Relatlimab and Nivolumab.
Menzies AM; Pires da Silva I; Trojaniello C; Vieu E; Amaria RN; Zimmer L; Lo SN; Burton EM; Tawbi HA; Schadendorf D; Grob JJ; Ascierto PA; Long GV
N Engl J Med; 2022 Apr; 386(17):1668-1669. PubMed ID: 35476655
[No Abstract] [Full Text] [Related]
16. Immune checkpoints and cancer development: Therapeutic implications and future directions.
Mehdizadeh S; Bayatipoor H; Pashangzadeh S; Jafarpour R; Shojaei Z; Motallebnezhad M
Pathol Res Pract; 2021 Jul; 223():153485. PubMed ID: 34022684
[TBL] [Abstract][Full Text] [Related]
17. Why are immune adverse events so common with checkpoint inhibitor therapy?
Lyubchenko T; Leung DYM; Goleva E
Ann Allergy Asthma Immunol; 2021 Jun; 126(6):608-610. PubMed ID: 33774187
[No Abstract] [Full Text] [Related]
18. Dendritic Cells and Their Role in Immunotherapy.
Gardner A; de Mingo Pulido Á; Ruffell B
Front Immunol; 2020; 11():924. PubMed ID: 32508825
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy Outcomes in Advanced Melanoma in Relation to Age.
Joshi K; Atwal D; Ravilla R; Pandey Y; Yarlagadda N; Kakadia S; Makhoul I; Hutchins L; Mahmoud F
Perm J; 2020; 24():. PubMed ID: 32097116
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint inhibitors and pre-existing antinuclear antibodies: the rheumatologist point of view.
Ceccarelli F; Botticelli A; Natalucci F; Olivieri G; Cirillo A; Alessandri C; Marchetti P; Conti F
Clin Transl Oncol; 2021 Sep; 23(9):1961-1962. PubMed ID: 33728870
[No Abstract] [Full Text] [Related]
[Next] [New Search]
